Mesothelioma Clinical Trials Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma This study is currently recruiting patients. Sponsored by Burzynski Research Institute For more information:National Cancer Institute (NCI)     RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. PURPOSE: This phase II trial studies the effectiveness of antineoplaston therapy in treating patients who have advanced mesothelioma. Condition Treatment or Intervention advanced malignant mesothelioma recurrent malignant mesothelioma Drug: antineoplaston A10 Drug: antineoplaston AS2-1 Procedure: biological response modifier therapy Procedure: cancer prevention intervention Procedure: complementary and alternative therapy Procedure: differentiation therapy This is a Phase II test In Phase II clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.  Study Type: Interventional Study Design: Treatment Official Title: Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Stage IV Mesothelioma Further Study Details:  OBJECTIVES: Provide treatment with antineoplastons A10 and AS2-1 to patients with stage IV mesothelioma. Describe the response to, tolerance to, and side effects of this regimen in these patients. OUTLINE: Patients receive gradually escalating doses of antineoplaston A10 and antineoplaston AS2-1 IV six times per day until the maximum dose is reached. Treatment continues for at least 3 months in the absence of disease progression or unacceptable toxicity. After 3 months, patients with stable or responding disease may continue treatment. Patients achieving complete response (CR) continue treatment for at least 8 months beyond CR. Patients are followed every 2 months for 1 year and then every 3 months for 1 year. PROJECTED ACCRUAL: Approximately 20-40 patients will be accrued for this study. Ages Eligible for Study:  1 Year and above,  Genders Eligible for Study:  Both Criteria DISEASE CHARACTERISTICS: Histologically confirmed stage IV mesothelioma that is unlikely to respond to existing therapy and for which no curative therapy exists Evidence of disease by CT scan or MRI